|
Market Closed -
Nasdaq
06:00:00 30/09/26 am AEST
|
After hours 10:00:00 am | |||
| 203.46 USD | +3.13% |
|
200.50 | -1.45% |
| 25/09 | Singapore Pushes Local mRNA Vaccine Production to Boost Pandemic Preparedness | MT |
| 24/09 | Healthcare Stocks Fall -- Healthcare Roundup | DJ |
| Market Cap | 81.23B 71.68B 67.82B 61.51B 115B 7,794B 116B 814B 314B 3,980B 305B 298B 12,808B | P/E 2026 * |
-24.3x | P/E 2027 * | -42.5x |
|---|---|---|---|---|---|
| Enterprise Value | 77.58B 68.46B 64.77B 58.74B 110B 7,444B 111B 777B 299B 3,801B 291B 285B 12,232B | EV / Sales 2026 * |
36.9x | EV / Sales 2027 * | 32.4x |
| Free-Float |
92.68% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MRNA | Delayed | |
CBOE
| MRNA | Real-time | |
|
Borsa Italiana
| 1MRNA | End-of-day quote | |
|
Tradegate
| 0QF | Real-time | |
|
Börse Stuttgart
| 0QF | Delayed | |
|
Xetra
| 0QF | Delayed | |
|
London S.E.
| 0A45 | Delayed | |
|
Swiss Exchange
| MRNA | Delayed | |
|
CBOE
| Real-time | ||
|
Boerse Muenchen
| 0QF | Real-time | |
|
Wiener Boerse
| MRNA | End-of-day quote | |
|
Kazakhstan S.E.
| MRNA_KZ | End-of-day quote | |
|
Mexican S.E.
| MRNA * | End-of-day quote | |
|
Deutsche Boerse AG
| 0QF | Delayed | |
|
Lima
| MRNAUS | End-of-day quote | |
|
CBOE
| 0A45 | Real-time | |
|
Swiss Exchange
| MRNA | Delayed |
Last Transcript: Moderna, Inc.
| 1 day | -1.45% | ||
| 1 week | +11.45% | ||
| Current month | +44.98% | ||
| 1 month | +47.45% | ||
| 3 months | +191.91% | ||
| 6 months | +310.53% | ||
| Current year | +589.93% |
| 1 week | 180.39 |  | 208.9 |
| 1 month | 130.38 | | 208.9 |
| Current year | 29.81 | | 208.9 |
| 1 year | 22.28 | | 208.9 |
| 3 years | 22.28 | | 208.9 |
| 5 years | 22.28 | | 376.65 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 01/03/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 06/09/2022 |
Stephen Hoge
PSD | President | 50 | 01/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 01/02/2012 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 01/03/2011 |
Francois Nader
BRD | Director/Board Member | 69 | 11/12/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 15/9/26 | Exercice | Chairperson | 193,185 | 0.0484% | ||
| 10/9/26 | Exercice | Chief Financial Officer | 74,508 | 0.0187% | ||
| 4/9/26 | Exercice | General Counsel | 29,298 | 0.0073% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.13% | +11.45% | +703.24% | +96.98% | 81.23B | |
| -0.23% | -6.64% | +33.84% | -8.80% | 74.94B | |
| +1.05% | +2.78% | -7.05% | -25.22% | 60.9B | |
| -1.07% | -0.43% | -10.19% | +32.27% | 47.22B | |
| -0.34% | -2.55% | -12.26% | +164.90% | 44.68B | |
| -0.71% | +0.76% | +63.93% | -11.65% | 33.55B | |
| -1.30% | -2.94% | +46.86% | +113.26% | 24.97B | |
| +0.73% | 0.00% | +53.28% | +95.55% | 15.17B | |
| -0.96% | -4.71% | +26.96% | +150.17% | 12.9B | |
| +0.40% | +1.60% | -29.28% | +383.92% | 13.01B | |
| Average | -0.38% | -0.87% | +86.93% | +99.14% | 40.86B | |
| Weighted average by Cap. | -0.46% | +0.32% | +152.46% | +62.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.1B 1.85B 1.75B 1.59B 2.98B 202B 3.01B 21.04B 8.11B 103B 7.89B 7.72B 331B | 2.44B 2.15B 2.04B 1.85B 3.46B 234B 3.5B 24.42B 9.41B 119B 9.15B 8.96B 384B |
| Net income | -3.31B -2.92B -2.77B -2.51B -4.7B -318B -4.75B -33.18B -12.79B -162B -12.44B -12.17B -522B | -1.94B -1.72B -1.62B -1.47B -2.76B -187B -2.79B -19.48B -7.51B -95.28B -7.3B -7.14B -307B |
| Net Debt | -3.65B -3.22B -3.05B -2.77B -5.19B -351B -5.24B -36.59B -14.1B -179B -13.72B -13.42B -576B | -2.17B -1.91B -1.81B -1.64B -3.08B -208B -3.11B -21.74B -8.38B -106B -8.15B -7.97B -342B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/09/26 | USD 203.46 | +3.13% | 13,277,922 |
| 28/09/26 | USD 197.28 | -0.80% | 13,359,640 |
| 25/09/26 | USD 198.88 | +2.08% | 13,944,982 |
| 24/09/26 | USD 194.82 | +6.98% | 16,605,461 |
| 23/09/26 | USD 182.11 | -0.25% | 17,727,824 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
